DRREDDY · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 57/100 — Quality 69 · Valuation 33 · Growth 72 · Momentum 46
| Share price | ₹1,223.10 |
| Market cap | ₹1.07 lakh Cr |
| P/E ratio | 18.9 |
| P/B ratio | 2.9 |
| ROE | 17.9% |
| ROCE | 22.0% |
| Dividend yield | 0.62% |
| Book value | ₹447.25 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹33,700 Cr | ₹4,158 Cr | 19.0% |
| 2025 | ₹32,644 Cr | ₹5,725 Cr | 26.0% |
| 2024 | ₹28,011 Cr | ₹5,578 Cr | 28.0% |
| 2023 | ₹24,670 Cr | ₹4,507 Cr | 26.0% |
| 2022 | ₹21,545 Cr | ₹2,182 Cr | 17.0% |
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufac